Posted by Michael Wonder on 17 Feb 2016
U.S. FDA grants breakthrough therapy designation for Roche’s investigational medicine ocrelizumab in primary progressive multiple sclerosis
17 February 2016 - Ocrelizumab is the first investigational medicine to receive breakthrough therapy designation in multiple sclerosis.
For more details, go to: http://www.roche.com/media/store/releases/med-cor-2016-02-17.htm
